Literature DB >> 27026682

C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Tiankai Li1, Heng-Jie Cheng1, Nobuyuki Ohte1, Hiroshi Hasegawa1, Atsushi Morimoto1, David M Herrington1, William C Little1, Weimin Li2, Che Ping Cheng2.   

Abstract

In heart failure (HF), the impaired left ventricular (LV) arterial coupling and diastolic dysfunction present at rest are exacerbated during exercise. C-type natriuretic peptide (CNP) is elevated in HF; however, its functional effects are unclear. We tested the hypotheses that CNP with vasodilating, natriuretic, and positive inotropic and lusitropic actions may prevent this abnormal exercise response after HF. We determined the effects of CNP (2 μg/kg plus 0.4 μg/kg per minute, i.v., 20 minutes) on plasma levels of cGMP before and after HF and assessed LV dynamics during exercise in 10 chronically instrumented dogs with pacing-induced HF. Compared with the levels before HF, CNP infusion caused significantly greater increases in cGMP levels after HF. After HF, at rest, CNP administration significantly reduced LV end-systolic pressure (PES), arterial elastance (EA), and end-diastolic pressure. The peak mitral flow (dV/dtmax) was also increased owing to decreased minimum LVP (LVPmin) and the time constant of LV relaxation (τ) (P < 0.05). In addition, LV contractility (EES) was increased. The LV-arterial coupling (EES/EA) was improved. The beneficial effects persisted during exercise. Compared with exercise in HF preparation, treatment with CNP caused significantly less important increases in PES but significantly decreased τ (34.2 vs. 42.6 ms) and minimum left ventricular pressure with further augmented dV/dtmax Both EES, EES/EA (0.87 vs. 0.32) were increased. LV mechanical efficiency improved from 0.38 to 0.57 (P < 0.05). After HF, exogenous CNP produces arterial vasodilatation and augments LV contraction, relaxation, diastolic filling, and LV arterial coupling, thus improving LV performance at rest and restoring normal exercise responses after HF.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27026682      PMCID: PMC4885509          DOI: 10.1124/jpet.115.231696

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  66 in total

1.  Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries.

Authors:  M Barton; J L Bény; L V d'Uscio; T Wyss; G Noll; T F Lüscher
Journal:  J Cardiovasc Pharmacol       Date:  1998-03       Impact factor: 3.105

2.  Bioactivity and metabolism of C-type natriuretic peptide in normal man.

Authors:  P J Hunt; A M Richards; E A Espiner; M G Nicholls; T G Yandle
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

3.  Effect of exercise on left ventricular-arterial coupling assessed in the pressure-volume plane.

Authors:  W C Little; C P Cheng
Journal:  Am J Physiol       Date:  1993-05

4.  Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure.

Authors:  M Nakamura; N Arakawa; H Yoshida; S Makita; K Hiramori
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

5.  Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow.

Authors:  C P Cheng; T Noda; T Nozawa; W C Little
Journal:  Circ Res       Date:  1993-04       Impact factor: 17.367

6.  C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems.

Authors:  R S Wright; C M Wei; C H Kim; M Kinoshita; Y Matsuda; L L Aarhus; J C Burnett; W L Miller
Journal:  J Am Coll Cardiol       Date:  1996-10       Impact factor: 24.094

7.  Atrial natriuretic peptide has different effects on contractility and intracellular pH in normal and hypertrophied myocytes from pressure-overloaded hearts.

Authors:  M Tajima; J Bartunek; E O Weinberg; N Ito; B H Lorell
Journal:  Circulation       Date:  1998-12-15       Impact factor: 29.690

8.  Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I.

Authors:  Kai C Wollert; Sevdalina Yurukova; Ana Kilic; Frank Begrow; Beate Fiedler; Stepan Gambaryan; Ulrich Walter; Suzanne M Lohmann; Michaela Kuhn
Journal:  Br J Pharmacol       Date:  2003-11-10       Impact factor: 8.739

9.  Changes in left ventricular diastolic function during exercise in patients with coronary artery disease.

Authors:  U Tebbe; K H Scholz; H Kreuzer; K L Neuhaus
Journal:  Eur Heart J       Date:  1987-10       Impact factor: 29.983

Review 10.  Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy.

Authors:  Ines Pagel-Langenickel; Jens Buttgereit; Michael Bader; Thomas H Langenickel
Journal:  J Mol Med (Berl)       Date:  2007-04-12       Impact factor: 4.599

View more
  2 in total

1.  Elevated C-type natriuretic peptide elicits exercise preconditioning-induced cardioprotection against myocardial injury probably via the up-regulation of NPR-B.

Authors:  Jiao Lu; Shan-Shan Pan
Journal:  J Physiol Sci       Date:  2016-08-24       Impact factor: 2.781

2.  Natriuretic Peptide Receptor B modulates the proliferation of the cardiac cells expressing the Stem Cell Antigen-1.

Authors:  Stéphanie Rignault-Clerc; Christelle Bielmann; Lucas Liaudet; Bernard Waeber; François Feihl; Nathalie Rosenblatt-Velin
Journal:  Sci Rep       Date:  2017-02-09       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.